ARID1A and prostate carcinoma: Therapeutic approaches inhibiting GAC may increase the efficacy of castration-resistant prostate cancer.140 In clear-cell ovarian cancer (OCCC), the glutaminase inhibitor CB-839 inhibited ARID1A (AT-rich interactive domain-containing protein 1A) -mutated PDX tumor growth.